MOG and myeloid sarcoma: All these differences led to the recognition of MOGAD as a separate entity, culminating in the International MOGAD Panel proposed criteria in 2023.8Of note, unlike in MS or NMOSD, the positivity of a biomarker (MOG-IgG) is indispensable for the fulfillment of the diagnostic criteria, making this a good example of the precision medicine approach.